Creative Financial Designs Inc. ADV Boosts Position in Johnson & Johnson (NYSE:JNJ)

Creative Financial Designs Inc. ADV boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 7.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 3,783 shares of the company’s stock after buying an additional 247 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Johnson & Johnson were worth $618,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Red Wave Investments LLC lifted its stake in Johnson & Johnson by 2.0% in the second quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after buying an additional 59 shares during the last quarter. Argus Investors Counsel Inc. lifted its stake in Johnson & Johnson by 0.6% in the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after buying an additional 61 shares during the last quarter. Alta Capital Management LLC lifted its stake in Johnson & Johnson by 0.4% in the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after buying an additional 61 shares during the last quarter. Paces Ferry Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 0.7% during the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after purchasing an additional 62 shares in the last quarter. Finally, Mason & Associates Inc raised its stake in shares of Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Citigroup lifted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective on the stock. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Sanford C. Bernstein dropped their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ opened at $168.74 on Monday. The business’s 50-day moving average price is $176.14 and its 200 day moving average price is $171.20. The stock has a market capitalization of $441.17 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.19 and a beta of 0.56. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.